Dyspareunia
Conditions
Keywords
Painful Intercourse, Sexual Dysfunction, Vaginal Dilator, Vaginal Moisturizer
Brief summary
In this randomized controlled trial, the investigators will assess the difference in mean patient-reported pain scores and sexual function between women with gynecologic or breast cancers experiencing dyspareunia (painful intercourse) who are assigned to vaginal dilator use with vaginal moisturizer (Intervention Group, n = 29) compared to vaginal moisturizer alone (Control Group, n = 29) over 16 weeks.
Detailed description
Between 2012 and 2016, approximately 94,000 women were diagnosed with a gynecologic cancer annually and over 1.2 million women with breast cancer between 2013 and 2017. It is well known that gynecologic and breast cancers, and their treatments including surgery, adjuvant chemotherapy and endocrine therapy, and radiation, result in significant effects on the female reproductive system which can lead to sexual dysfunction. In the U.S., sexual dysfunction among gynecologic oncology patients has been reported to be as high as 90%, and over 70% among breast cancer patients. Patients who receive chemotherapy and/or endocrine therapy commonly experience dyspareunia, vaginal dryness, and challenges with desire and orgasm due to a low estrogen state. In fact, among patients with breast cancer, unaddressed sexual side effects from adjuvant endocrine therapy are one reason for early discontinuation. Hysterectomy and oophorectomy, including for ovarian cancer risk-reduction, can cause similar physical symptoms in addition to psychologic effects like anxiety related to sexual intercourse.
Interventions
OTHERVaginal Moisturizer
Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
DEVICEVaginal Dilator
Vaginal dilator will be inserted vaginally and used daily, but at least 3 times per week.
Sponsors
Columbia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients 18 years or older * English or Spanish speaking * Patients currently or previously treated for: * Gynecologic cancer (surgery, chemotherapy, adjuvant vaginal brachytherapy) * Breast cancer (chemotherapy, aromatase inhibitors, or selective estrogen receptor modulators; surgical menopause) * Current desire for penetrative sexual activity * Endorsement of at least one of the following in the last 6 months: * Dyspareunia during penetrative sexual activity * Reported sensation of penetrative object (partner's penis, sex toy) not fitting in the vagina * Avoidance of penetrative sexual activity due to fear of pain * Physically able to insert a vaginal dilator by themselves * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients with prior primary or upfront pelvic radiation * Patients with whole pelvic radiation at any time * Patients with a history of chronic pelvic pain * Patients with vulvodynia as noted on baseline pelvic exam with \> 5/10 pain score during an external exam with a cotton swab * Patients with prior vaginal dilator use for any indication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in Mean Patient-Reported Pain Scores During Sexual Activity | Up to 16 weeks | The difference in mean patient-reported pain scores will be calculated, during penetrative sexual activity before and after randomization to vaginal dilator use with vaginal moisturizer or vaginal moisturizer alone. Pain scores will be assessed using a 10cm vial analog scale (VAS), in which 0 indicates no pain and 10 indicates most pain (worst outcome). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in Mean Patient-Reported Pain Scores During Speculum Exam | Up to 16 weeks | The difference in mean patient-reported pain scores will be calculated, during speculum exam before and after randomization to vaginal dilator use with vaginal moisturizer or vaginal moisturizer alone. Pain scores will be assessed using a 10cm vial analog scale (VAS), in which 0 indicates no pain and 10 indicates most pain (worst outcome). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Sexual Function based on the PROMIS SexFS Score (Version 2.0) | Up to 16 weeks | The Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual Function (SexFS) assesses over the last 30 days interest in sexual activity, lubrication, vaginal discomfort, clitoral discomfort, labial discomfort, erectile function, orgasm ability, orgasm pleasure and is customizable so that study designers can select relevant domains and items for their study. Raw scores can range from 2 to 10 (very or very much), which is then converted to a T-score found in the appendix of the survey. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. Therefore a person with a T-score of 40 is one SD below the mean. The standardized T-score is reported as the final score for each participant for each domain. |
Countries
United States
Outcome results
None listed